XOMA Corp (XOMA)-Financial and Strategic SWOT Analysis Review

XOMA Corp (XOMA)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH81739FSA
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

XOMA Corp (XOMA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company operations and business divisions.

Corporate strategy-Analyst summarization of the company business strategy.

SWOT Analysis-A detailed analysis of the company strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that discovers, develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358, X213 and X129. XOMA X358 is a human negative allosteric modulating insulin receptor antibody; X213 (formerly LFA 102) is an allosteric inhibitor of prolactin action; X129 is a potent fragment of a monoclonal antibody with negative allosteric modulation activity. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corp Key Recent Developments

May 18,2017: XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development

May 09,2017: XOMA Reports First Quarter 2017 Financial Results

Mar 16,2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results

Feb 16,2017: XOMA Appoints Matthew Perry to its Board of Directors

Nov 09,2016: XOMA Reports Third Quarter 2016 Achievements and Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

XOMA Corp-Key Facts 5

XOMA Corp-Key Employees 6

XOMA Corp-Key Employee Biographies 7

XOMA Corp-Major Products and Services 8

XOMA Corp-History 9

XOMA Corp-Company Statement 13

XOMA Corp-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

XOMA Corp-Business Description 16

XOMA Corp-Corporate Strategy 17

XOMA Corp-SWOT Analysis 18

SWOT Analysis-Overview 18

XOMA Corp-Strengths 18

XOMA Corp-Weaknesses 19

XOMA Corp-Opportunities 20

XOMA Corp-Threats 21

XOMA Corp-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

XOMA Corp, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

May 18, 2017: XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development 32

May 09, 2017: XOMA Reports First Quarter 2017 Financial Results 33

Mar 16, 2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results 34

Feb 16, 2017: XOMA Appoints Matthew Perry to its Board of Directors 36

Nov 09, 2016: XOMA Reports Third Quarter 2016 Achievements and Financial Results 37

Aug 03, 2016: XOMA Reports Second Quarter 2016 Achievements and Financial Results 39

May 04, 2016: XOMA Reports First Quarter 2016 Operational Achievements and Financial Results 41

Mar 09, 2016: XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results 43

Section 6-Appendix 45

Methodology 45

Ratio Definitions 45

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

XOMA Corp, Performance Chart (2012-2016) 26

XOMA Corp, Ratio Charts 28

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30

List of Tables

XOMA Corp, Key Facts 5

XOMA Corp, Key Employees 6

XOMA Corp, Key Employee Biographies 7

XOMA Corp, Major Products and Services 8

XOMA Corp, History 9

XOMA Corp, Subsidiaries 15

XOMA Corp, Key Competitors 22

XOMA Corp, Ratios based on current share price 23

XOMA Corp, Annual Ratios 24

XOMA Corp, Annual Ratios (Cont...1) 25

XOMA Corp, Interim Ratios 27

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

XOMA Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

XOMA Corp, Recent Deals Summary 31

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

select a license

Single User License
USD 125 INR 8070
Site License
USD 250 INR 16140
Corporate User License
USD 375 INR 24210

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com